CURE RESOURCES

A resource listing of articles, reports, websites and ongoing clinical trials related to the research effort to cure HIV infection.

Last updated 2/7/2012

TAG PUBLICATIONS

• Report and Commentary from the Fifth International Workshop on HIV Persistence during Therapy - Posted February 2012
• HIV Cure-Related Clinical Research Workshop - A report, October 2011
• The i-Base TAG 2011 Pipeline Report - Research Toward a Cure section on pages 81-84, September 2011
• Cure Research Momentum Accelerates - tagline, Fall 2011
• What We Need to Cure AIDS? - tagline, Fall 2011
• Clinical Trials Will Play a Vital Role in Charting the Path to an HIV Cure - tagline, Summer 2011
• Reinvigorating the Search for a Cure - tagline, Fall 2010
• NIAID Workshop: Elimination of HIV Reservoirs -tagline, Winter 2010
• Looking for a Cure for AIDS - What are the Mechanisms of HIV Latency and Persistence? - tagline, Winter 2009

ADVOCACY

• The Rome Statement for an HIV Cure: Major HIV/AIDS Stakeholders Call for HIV Cure Research to be Accelerated - Sign-on statement, July 2011

COMMUNITY-BASED ARTICLES AND REPORTS

• Report from the 5th International Workshop on HIV Persistence during Therapy - NATAP, December 2011
• Questions Toward a Cure - AIDSMeds, December 6, 2011
• A Primer on What’s Up With Cure Research - Project Inform, December 5, 2011
• Post-Conference Report Provides HIV Cure Roadmap - AIDSMeds, November 2, 2011
• Patient No More - POZ Magazine, June 2011
• HIV Eradication: Time to Talk about a Cure - BETA, Winter/Spring 2011
• New Hope for a Cure  - ACHIEVE, Spring 2011
• What Would You Do to Cure HIV? - AIDSMeds, May 2011
• As Cure Search Intensifies, Questions Arise - amfAR, May 2011
• Will You Be a Hero for the Cure? - The Body, May 2011
• Why AIDS Must Be Cured - By Kate Krauss (Executive Director, AIDS Policy Project) and Winstone Zulu (Health Triangle and Global Friends in Action Trust, Zambia), POZ Blogs, March 15, 2011
• Towards a cure for all (part 2): How we might do it - NAM HIV Treatment Update, March 2011
• Towards a cure for all (part 1) - NAM HIV Treatment Update, January/February 2011
• From Mice Into Men - POZ Magazine, October/November 2010
• The Doctor Is In - Interview with Dr. Anthony Fauci - POZ Magazine, October/November 2010
• The Cure? - Positively Aware Special Issue, September/October 2010
• AIDS Cure Research For Everyone: A Beginner’s Guide to How It’s Going and Who’s Paying for It - AIDS Policy Project, July 2010

MAINSTREAM MEDIA ARTICLES

• New Hope of a Cure for H.I.V. - New York Times, November 28, 2011
• Toward an H.I.V. Cure - International Herald Tribune, June 4, 2011
• The Man Who Had HIV and Now Does Not - New York Magazine, May 29, 2011
• Sangamo's Bet Against AIDS: Gene Therapy - Businessweek, February 14, 2011
• HIV-Resistant Cells Work in Mice. Can They Help Humans? -  Los Angeles Times, August 21, 2010

SCIENTIFIC PUBLICATIONS (Open Access)

• Achieving a cure for HIV infection: do we have reasons to be optimistic? - Journal of Antimicrobial Chemotherapy, January 31, 2012
• HIV Reservoirs and the Possibility of a Cure for HIV Infection - Journal of Internal Medicine, December 2011
• HDAC Inhibitors in HIV - Immunology and Cell Biology, published online November 2011
• HIV Latency - Cold Spring Harbor Perspectives, September 2011
• Big Bolus for HIV/AIDS Cure Research - Science Insider, July 11, 2011
• The search for a cure for persistent HIV reservoirs - AIDS Reviews, April-June 2011
• HIV cure and eradication: how will we get from the laboratory to effective clinical trials? - AIDS, April 24, 2011 (full text courtesy of NATAP)
• Eradication therapies for HIV infection: time to begin again - AIDS Research and Human Retroviruses, Febuary 2011
• Finding a cure for HIV: will it ever be achievable? - Journal of the International AIDS Society 2011, 14:4, January 2011
• Workshop Report and Abstracts - Towards a Cure: HIV Reservoirs and Strategies to Control Them - Journal of the International AIDS Society 2010, 13(Suppl 3):I1, November 2010
• What Do We Need to Do to Cure HIV Infection? - Topics in HIV Medicine, Aug/Sept 2010
• HIV Cure: Controversy, Consensus, and a Consortium - AIDS Research and Human Retroviruses, 26(9): 943-946, September 2010

GENERAL RESOURCES

• AIDS Policy Project
• AIDS Policy Project Cure Blog
• amfAR Research Consortium on HIV Eradication (ARCHE)    
• Martin Delaney Collaboratory
• Reference Portal on HIV reservoirs & Eradication Strategies
• TAG’s Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Website of Timothy R. Brown, "The Berlin Patient"

TRIALS & RESEARCH STUDIES LISTED IN CLINICALTRIALS.GOV

It must be stressed that none of these studies are expected to cure HIV infection, they represent research working toward that goal. Click links for detailed information, enrollment criteria and contacts.

• Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects (GCHT01)
  
  Estimated Enrollment: 30
  Site: University of Miami School of Medicine, AIDS Clinical Research unit
   
• Tissue Drug Levels of HIV Medications
  Estimated Enrollment: 40
  Site: University of Minnesota, Minneapolis, Minnesota
   
• Allogeneic Transplant in HIV Patients (BMT CTN 0903)
  
  For HIV positive individuals with chemotherapy-sensitive hematological malignancies requiring stem cell transplants. The study will attempt to find stem cell donors who are homozygotes for the delta32 mutation for CCR5, in an attempt to reproduce the cure of HIV infection achieved in the "Berlin Patient."
   
  Estimated Enrollment: 15
  Sites: City of Hope National Medical Center, Duarte, California
  University of California Los Angeles, Los Angeles, California
  University of California San Francisco, San Francisco, California
  University of Florida College of Medicine, Gainesville, Florida
  H. Lee Moffitt Cancer Center, Tampa, Florida
  Johns Hopkins, Baltimore, Maryland
  Memorial Sloan-Kettering Cancer Center, New York, New York
  Weill Cornell Medical College, New York, New York
  University of Texas MD Anderson Cancer Center, Houston, Texas
  Texas Transplant Institute, San Antonio, Texas
  University of Utah, Salt Lake City, Utah
   
• Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Antiretroviral Therapy
  Estimated Enrollment: 20
  Site:The Alfred Hospital - Infectious Diseases Unit, Melbourne, Victoria, Australia
   
• The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
  Estimated Enrollment: 20
  Site: The University of North Carolina at Chapel Hill, North Carolina
   
• Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
  Estimated Enrollment: 45
  Sites: National Institutes of Health Clinical Center, Bethesda, Maryland; University of Pittsburgh, Pennsylvania
   
• Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
  Estimated Enrollment: 13
  Sites: UCLA Center for AIDS Research and Education, Los Angeles, California; Quest Clinical Research, San Francisco, California
   
• Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
  Estimated Enrollment: 14
  Sites: UCLA CARE Center, Los Angeles, California; Quest Clinical Research, San Francisco, California
   
• Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger)
  Estimated Enrollment: 18
  Sites: Jacobi Medical Cener, Bronx, New York; University of Pennsylvania, Philadelphia, Pennsylvania
   
• Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)
  Current antiretroviral therapy regimen plus raltegravir and maraviroc
  Immune-based therapy: IL-7
  Estimated Enrollment: 28
  Sites: Groupe Hospitalier Pitié-Salpêtrière, Paris, France; San Raffaele Scientific Institute, Milan, Italy; Fundacio Irsicaixa, Badalona, Spain; University Hospital Clinic of Barcelona, Barcelona, Spain; Royal Free Hospital, London, United Kingdom

• Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir (EraMune02)
  DNA + HIV-rAd5 vaccine
  Antiretroviral therapy intensification with raltegravir, maraviroc
  Estimated Enrollment: 28
  Sites: University of California San Francisco, San Francisco, California; Northwestern University, Chicago, Illinois; Cornell University, New York, New York

• Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
  Estimated Enrollment: 20
  Open label 500mg disulfiram (Antabuse) per day by mouth for 14 days
  Sites: San Francisco General Hospital, California; Johns Hopkins University, Baltimore, Maryland
   
• HIV Persistence and Viral Reservoirs
  Drugs: raltegravir, tenofovir/emtricitabine
  Estimated Enrollment: 20
  Site: San Francisco General Hospital, California

• Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
  Biological: AGS-004 (personalized therapeutic HIV vaccine)
  Estimated Enrollment: 42
  Sites: USA

• University of Alabama at Birmingham, Birmingham, Alabama
• UCDavis Research Office at CARES, Sacramento, California,
• Jacobi & North Central Bronx Hospitals, Bronx, New York
• AIDS Clinical Trials Unit, Chapel Hill, North Carolina
• Duke University Medical Center, Durham, North Carolina
• Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice, Philadelphia, Pennsylvania, United States, 191002

Canada, Quebec

• Montreal Chest Institute, Immunodeficiency Dept., Montréal, Quebec
• Clinique médicale l'Actuel, Montréal, Quebec
• Clinique Médical du Quartier Latin, Montréal, Quebec